Change in ADS ratio

AstraZeneca PLC - Change in ADS ratio

AstraZeneca PLC (the "Company") today announces an intended ratio change to its NYSE-listed sponsored Level 2 American Depositary Receipt ("ADR") programme. The current ratio is one (1) American Depositary Share ("ADS") per one (1) Ordinary Share. The new ratio will be two (2) ADSs per one (1) Ordinary Share. The expected effective date for the ratio change is 27 July 2015. There will be no change to the underlying Ordinary Shares.

ADS holders at the close of business New York time on the record date, 22 July 2015, will receive a distribution of one additional ADS for every ADS held. The new ADSs are expected to be distributed on 24 July 2015. No action is required by ADS holders to effect this change.

Contact details for Citibank, N.A., the Company's ADR depositary, can be found below.

A C N Kemp

Company Secretary

26 June 2015

 

CONTACT

Citibank Shareholder Services

PO Box 43077 
Providence
RI 02940-3077
US
Tel (toll free in the   US): +1-888-697-8018
Tel (outside the US): +1-781-575-4555 

 Media Enquiries

Esra Erkal-Paler +44 20 7604 8030   (UK/Global)
Jacob Lund +46   8 553 260 20 (Sweden)
Michele Meixell + 1 302 885 6351 (US)

Investor Enquiries

UK
Thomas Kudsk Larsen +44 20 7604 8199 mob: +44 7818 524185
Eugenia Litz Respiratory,   Inflammation and Autoimmunity +44 20 7604 8233 mob: +44 7884 735627
Nick Stone Cardiovascular andMetabolic Disease +44 1763 263 994 mob: +44 7717 618834
Karl Hård Oncology +44 20 7604 8123 mob: +44 7789 654364
Craig Marks Infection,   Neuroscience and Gastrointestinal Disease +44 20 7604 8591 mob: +44 7881 615764
Christer Gruvris +44 20 7604 8126 mob: +44 7827 836825
US
Dial / Toll-Free 301-398-3251  866-381-7277

 

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe

Documents & Links